| Name | Title | Contact Details |
|---|
Prestige Care is a Washington-based provider of senior living and long-term care in the Western region of the United States. Founded in 1985, Prestige`s care philosophy is rooted in a set of shared core values that deliver on a promise to provide unmatched quality care, led by a compassionate heart. Across the company, Prestige team members strive to personally touch lives, guided by the four pillars of our core values: respect, integrity, commitment and trust. Prestige`s core values are instilled by the legacy of Sarah Delamarter, a pioneer in the long-term care industry. Today, Sarah`s legacy lives on through Prestige Care Inc, which includes 72 senior care communities across eight states. Prestige Care is a complete senior services organization, which provides Nursing and Rehabilitation services, Memory Care, and Assisted Living and Retirement Services. Prestige communities` commitment to excellence has been recognized by the American Healthcare Association with multiple Bronze and Silver quality care awards. In 2012 Prestige received the Innovators Award from the International Council on Active Aging® (ICAA), for its Expressions Memory Care program. Expressions is a life-affirming, activity-rich residential program for individuals with Alzheimer`s disease and other forms of dementia who seek community-based care to help alleviate the affects of the disease for patients and their families.
PharmaNet is an international drug development company employing about 1,500 professionals worldwide.
Willis-Knighton Health System, headquartered in Shreveport, Louisiana, is a not-for-profit community healthcare corporation with four general acute care hospitals and affiliate relationships with several rural hospitals. It is the largest nongovernmental employer in the region, employing more than 6,500 people.
Smart devices and digital support that connect patients to care, with clinically-proven results https://t.co/zoMxznOfwA
BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.